Pfizer (NYSE:PFE – Get Rating) received a $47.00 price target from investment analysts at The Goldman Sachs Group in a research report issued to clients and investors on Tuesday, Borsen Zeitung reports. The Goldman Sachs Group’s price objective indicates a potential upside of 0.60% from the stock’s previous close.
PFE has been the topic of a number of other reports. Berenberg Bank set a $44.00 target price on shares of Pfizer in a research note on Wednesday, September 14th. SVB Leerink boosted their price target on shares of Pfizer from $48.00 to $49.00 and gave the company a “market perform” rating in a research report on Thursday, November 3rd. Morgan Stanley boosted their price target on shares of Pfizer from $50.00 to $51.00 and gave the company an “equal weight” rating in a research report on Wednesday, November 2nd. UBS Group set a $55.00 price target on shares of Pfizer in a research report on Thursday, November 3rd. Finally, JPMorgan Chase & Co. set a $50.00 price target on shares of Pfizer in a research report on Tuesday, November 1st. Nine analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, Pfizer presently has a consensus rating of “Moderate Buy” and an average target price of $56.44.
Pfizer Stock Down 1.3 %
PFE opened at $46.72 on Tuesday. The company has a quick ratio of 1.20, a current ratio of 1.42 and a debt-to-equity ratio of 0.39. The stock has a market cap of $262.21 billion, a price-to-earnings ratio of 8.98, a PEG ratio of 0.59 and a beta of 0.69. Pfizer has a twelve month low of $41.44 and a twelve month high of $61.71. The company’s 50-day moving average price is $45.11 and its two-hundred day moving average price is $48.56.
Hedge Funds Weigh In On Pfizer
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands.
- Get a free copy of the StockNews.com research report on Pfizer (PFE)
- Is Triple-Digit Growth Ahead For Digital Ad Platform Trade Desk?
- EV Maker Lucid Falls On Declining Orders, Rivian Up On Guidance
- DoorDash Outperforms Despite Losses – Is It Time To Buy?
- Analysts Rate DraftKings a Moderate Buy As Growth Slows
- Goodyear Tire & Rubber Stock is Becoming a Mighty Good Bargain
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.